A cohort of 222 anti-CD20 treated patients with multiple sclerosis followed through the COVID-19 pandemic: Attenuated humoral but robust cellular immune responses after vaccination and infection

Tatjana Schwarz, M.Sc.[1,*], Carolin Otto, MD[2,*], Terry C. Jones, PhD[1], Florence Pache, MD[2], Patrick Schindler, MD[2], Moritz Niederschweiberer[2], Felix A. Schmidt, MD[2], Christian Drosten, MD[1] ,Victor M. Corman, MD[1,3#], Klemens Ruprecht, MD[2,#]

[1]Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, and German Centre for Infection Research (DZIF), associated partner, Berlin, Germany

[2]Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

[3]Labor Berlin - Charité Vivantes GmbH, Berlin, Germany

*contributed equally

[#]these authors jointly supervised this work

Co-Corresponding authors:
Dr. med. Victor M. Corman
Institute of Virology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany, phone +49 30 450 625 095, fax +49 30 450 752 5907, e-mail: victor.corman@charite.de

and

Prof. Dr. med. Klemens Ruprecht
Department of Neurology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany, phone: ++49 30 450 660 374, fax: ++49 30 450 560 922, e-mail: klemens.ruprecht@charite.de

Key Points

Question: Do anti-CD20 treated patients with multiple sclerosis (pwMS) develop humoral and cellular immune responses after SARS-CoV-2 vaccination/infection?

Findings: In a prospective cohort study, levels, avidity and neutralizing capacity of SARS-CoV-2 specific antibodies were diminished, but SARS-CoV-2 specific T cell responses preserved in pwMS following SARS-CoV-2 vaccination/infection. SARS-CoV-2 antibody levels and functionality increased with increasing time from the last anti-CD20 therapy to the second SARS-CoV-2 vaccination.

Meaning: A robust T cell response following vaccinations/infections may contribute to protection against COVID-19 in anti-CD20 treated pwMS. Time between anti-CD20 therapy and vaccination might be key for sufficient SARS-CoV-2 specific humoral immune responses.

Abstract

Importance: Data on immune responses following SARS-CoV-2 vaccinations/infections and on detection rate of SARS-CoV-2 infections in anti-CD20 treated patients with multiple sclerosis (pwMS) are important for guiding management of pwMS during the current SARS-CoV-2 pandemic.

Objective: To analyze humoral and cellular immune responses to SARS-CoV-2 vaccinations/infections and to determine the detection rate of SARS-CoV-2 infections in anti-CD20 treated pwMS.

Design: Prospective single-center cohort study from March 2020 to August 2021.

Setting: MS referral center, Charité - Universitätsmedizin Berlin, Germany.

Participants: 222 consecutive pwMS (128 [57.7%] female, median [range] age 39 [17-81] years). 181 patients were on anti-CD20 therapy at study inclusion, 41 began anti-CD20 therapy during the study. Hospital employees (HE, n=19) served as controls.

Exposures: pwMS were exposed to anti-CD20 therapy for 169.5 patient years. 51 patients under anti-CD20 treatment, 14 patients before anti-CD20 treatment, and 19 HE were vaccinated twice against SARS-CoV-2.

Main outcomes: SARS-CoV-2 spike protein immunoglobulin (Ig)G (ELISA and immunofluorescence), IgA (ELISA), IgG to four recombinant SARS-CoV-2 antigens (solid phase immunoassay), neutralizing capacity of SARS-CoV-2 antibodies (plaque reduction neutralization test), SARS-CoV-2 IgG avidity (modified ELISA), and SARS-CoV-2 specific T cells (interferon-γ release assay).

Results: Following two SARS-CoV-2 vaccinations, median (IQR) levels of SARS-CoV-2 spike protein IgG (OD ratio: 1.2 [0.1-5.1] vs. 9.0 [6.8-9.9] vs. 8.8 [8.0-9.4], $p<0.0001$), neutralizing capacity (PRNT50 Titer: 40 [0-80] vs. 640 [80-640] vs. 640

[320-640], $p \leq 0.006$), and antibody avidity (43.6% [14.8-54.6%] vs. 84.1% [53.1-86.8%] vs. 89.7 [76.8-93.4%], $p \leq 0.003$) were lower in anti-CD20 treated pwMS than in pwMS before initiation of anti-CD20 therapy and in HE. All anti-CD20 treated pwMS vaccinated twice developed SARS-CoV-2 specific T cells, whose levels did not differ from those of pwMS before initiation of anti-CD20 therapy and HE. SARS-CoV-2 IgG levels (r=0.42, p=0.002) and antibody avidity (r=0.70, p<0.001) increased with time between anti-CD20 infusion and second vaccination. The detection rate of SARS-CoV-2 infections in anti-CD20 treated pwMS (2.36/100 patient years) was similar to that of RT-PCR confirmed SARS-CoV-2 cases in the general Berlin population (3.75/100 person years) during the study period.

Interpretation: These findings are relevant for treatment decisions as well as management of SARS-CoV-2 vaccinations in pwMS.

Main Text

Introduction

Management of immunotherapies and vaccinations against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are key issues in the clinical care of patients with multiple sclerosis (pwMS) during the current SARS-CoV-2 pandemic.[1,2] Of particular concern, B-cell depleting anti-CD20 therapies have been associated with an increased risk of infections and decreased humoral immune responses to vaccinations.[1–6] Indeed, serum levels of SARS-CoV-2 immunoglobulin (Ig)G following SARS-CoV-2 vaccinations and infections are reduced in anti-CD20 treated pwMS.[7–9] Nevertheless, in addition to antibody levels, protection from infection, and especially from severe courses of coronavirus disease-19 (COVID-19), may depend on neutralizing capacity and avidity of anti-SARS-CoV-2 antibodies as well as on induction of SARS-CoV-2 specific T cells.[10–12] However, data on anti-SARS-CoV-2 antibody neutralization capacity and avidity in anti-CD20 treated pwMS are scarce. While very recent studies suggest that SARS-CoV-2 specific T cellular immune responses may be preserved in pwMS under anti-CD20 therapy, given the importance of these findings, independent confirmation appears warranted.[13,14]

The first laboratory-confirmed patient with COVID-19 in Germany was reported on January 27, 2020.[15] To monitor SARS-CoV-2 specific humoral immune responses in anti-CD20 treated pwMS, we started to prospectively collect sera for SARS-CoV-2 antibody determinations from pwMS treated with anti-CD20 therapies at the MS outpatient clinic, Charité Campus Mitte, Charité - Universitätsmedizin Berlin, Germany, on March 5, 2020. Following the start of the SARS-CoV-2 vaccination campaign in Germany in January 2021, we also assessed T cell responses to SARS-CoV-2 by interferon-γ release assays (IGRA).[16]

Here, we report results of detailed analyses of humoral and cellular immune responses following SARS-CoV-2 vaccinations/infections and the SARS-CoV-2 detection rate in a single-center cohort of 222 anti-CD20 treated pwMS followed through the first 17 months of the SARS-CoV-2 pandemic.

Materials and Methods

Ethical approval

The study was approved by the ethical committee of Charité - Universitätsmedizin Berlin (EA2/152/21 and EA1/068/20).

Patients

Between March 5, 2020, and August 6, 2021 (herein referred to as study period), 222 consecutive pwMS, who were treated with at least one intravenous infusion of anti-CD20 therapy, were enrolled at the MS outpatient clinic, Charité Campus Mitte, Charité - Universitätsmedizin Berlin, Germany, in a prospective observational study. Patients were either already treated with anti-CD20 therapy before March 5, 2020, or began anti-CD20 therapy during the study period. Details of the patients' treatments and the sampling scheme are described in the **Supplement**.

SARS-CoV-2 specific humoral and cellular immune responses

To detect anti-SARS-CoV-2 antibodies, a SARS-CoV-2 spike subunit 1 (S1) IgG and IgA ELISA Kit (Euroimmun, Lübeck, Germany) were used.[17] To confirm results obtained by ELISA, a recombinant anti-SARS-CoV-2 spike immunofluorescence test (IFT)[18] and a microarray-based multiparametric immunoassay for detection of IgG

antibodies against spike and nucleocapsid protein (SeraSpot®Anti-SARS-CoV-2 IgG, Seramun Diagnostica GmbH, Heidesee, Germany) were applied.[17,19] The neutralizing capacity of SARS-CoV-2 antibodies was analyzed by a plaque reduction neutralization test (PRNT), using authentic SARS-CoV-2.[18,20] IgG avidity maturation was determined by a modified SARS-CoV-2 S1 ELISA (Euroimmun).[19] SARS-CoV-2 specific T cells were monitored utilizing a commercially available IGRA (Euroimmun).[19] Further details of the applied test systems and the applied statistical analyses are provided in the **Supplement**.

Results

Patients and controls

Between March 5, 2020, and August 6, 2021, 222 consecutive pwMS (177 with relapsing-remitting MS [RRMS] and 45 with primary progressive MS [PPMS]) were treated with at least one infusion of anti-CD20 therapy (220 with ocrelizumab and 2 with rituximab) at the MS outpatient clinic, Charité Campus Mitte, Charité - Universitätsmedizin Berlin, and included in this study. According to treatment status at the date of the latest sample collection, pwMS were grouped into those before initiation of anti-CD20 therapy (n=41) and those under anti-CD20 therapy (n=181). Age, female/male ratio, the proportions of patients with RRMS/PPMS, the expanded disability status scale (EDSS) score, and the percentages of patients with any previous or at least two previous immunotherapies did not differ between pwMS before initiation of anti-CD20 therapy and under anti-CD20 therapy (**Table 1**, for immunotherapies prior to anti-CD20 therapy see **eTable 1**). Nineteen hospital employees (HE), who were on average 7.5 years younger than pwMS, were included as controls (**Table 1**).

Figure 1 provides an overview of the pwMS and samples analysed in this work and summarizes the number of patients who received one or two SARS-CoV-2 vaccinations and the number of SARS-CoV-2 infections among pwMS under and before initiation of anti-CD20 therapy.

Humoral immune responses to SARS-CoV-2 vaccinations

From the 222 pwMS included in this study, a total of 397 serum samples were collected during the study period (see **eFigure 1A** for an overview of samples per study month and **eFigure 1B** for courses of anti-SARS-CoV-2 S1 IgG levels in individual patients). During the study period, 51 pwMS under anti-CD20 therapy and 14 pwMS before initiation of anti-CD20 therapy were vaccinated twice against SARS-CoV-2 (**Figure 1**). Vaccinations were performed with the BNT162b2 vaccine in 45 of 51 (88.2%, 95%CI: 76.7-94.5) pwMS under anti-CD20 therapy and 10 of 14 (71.4%; 95%CI: 45.4-88.3) pwMS before initiation of anti-CD20 therapy (for further vaccines used, see **eFigure 2A**). For analysis of humoral immune responses to SARS-CoV-2 vaccinations, we used the latest available sample from pwMS (median [IQR] interval from the second vaccination to blood withdrawal: 40 [31-47] days). Nineteen HE vaccinated twice against SARS-CoV-2 with BNT162b2/BNT162b2 (n=7) or ChAdOx1/BNT162b2 (n=12) served as controls (median [IQR] interval from the second vaccination to blood withdrawal: 28 [22-29] days).

After the second SARS-CoV-2 vaccination, the frequency of patients with anti-SARS-CoV-2 S1 IgG antibodies above the assay threshold for reactivity was lower in anti-CD20 treated pwMS (26/51, 50.9%, 95%CI: 37.7-64.3%) than in pwMS before anti-

CD20 therapy (13/14, 92.9%, 95%CI: 68.5-97.6%, *p*=0.005) and HE (19/19, 100%, 95% CI: 83.2-100%, *p*<0.0001) (**eTable 2**). Accordingly, anti-SARS-CoV-2 S1 IgG levels were lower in anti-CD20 treated pwMS (median [IQR] OD ratio 1.2 [0.1-5.1]) compared to pwMS before anti-CD20 therapy (9.0 [6.8-9.9], *p*<0.0001) and to HE (8.8 [8.0-9.4], *p*<0.0001) (**Figure 2A**, **eFigure 2B**, **eTable 2**). No significant difference of anti-SARS-CoV-2 S1 IgG antibodies was detected between pwMS before anti-CD20 therapy and HE (*p*=1). Similar results were obtained for anti-SARS-2 S1 IgA antibodies (**eFigure 2C**). Likewise, anti-CD20 treated pwMS vaccinated twice had lower IgG levels against a recombinant SARS-CoV-2 full spike protein as detected by IFT (**eFigure 2D**). Furthermore, using another microarray based immunoassay, anti-CD20 treated pwMS vaccinated twice had lower IgG levels against the receptor binding domain of the SARS-CoV-2 spike protein and the full spike protein (**eFigure 2E, F**). Antibodies against the SARS-CoV-2 nucleocapsid, indicating past SARS-CoV-2 infection, were undetectable in pwMS vaccinated twice (**eFigure 2G**).

We next analysed the functionality of SARS-CoV-2 specific antibodies. Only 18/26 (69.2%, 95%CI: 50.0-83.5%) anti-CD20 treated pwMS with reactive anti-SARS-CoV-2 S1 IgG as detected by ELISA exhibited neutralizing antibodies against an authentic SARS-CoV-2 isolate with a titer of 20 or greater compared to 12/13 (92.3%, 95%CI: 66.7-99.6%, *p*=0.23) pwMS before anti-CD20 therapy and 19/19 (100%, 95%CI: 83.2-100%, *p*=0.01) HE (**eTable 2**). In addition, neutralizing capacity was significantly lower in anti-CD20 treated pwMS (median [IQR] PRNT50 Titer: 40 [0-80]) than in pwMS before anti-CD20 therapy (PRNT50 Titer: 640 [80-640], *p*=0.006) and in HE (PRNT50 Titer: 640 [320-640], *p*<0.0001) (**Figure 2B, eFigure 2H**).

Impaired functionality of SARS-CoV-2 antibodies was also reflected in the maturation of IgG avidity: After two vaccinations, only 4/26 (15.4%, 95%CI: 6.2-33.5%) anti-CD20 treated pwMS had high anti-SARS-CoV-2 S1 IgG avidity indices compared to 10/13 (76.9%, 95%CI: 49.7-91.8%, p=0.0003) pwMS before anti-CD20 therapy and 17/19 (85.5%, 95%CI: 68.6-98.1%, p<0.0001) HE (**eTable 2**). Accordingly, median (IQR) relative avidity index was lower in anti-CD20 treated pwMS (43.6% [14.8-54.6%]) than in pwMS before anti-CD20 therapy (84.1% [53.1-86.8%], p=0.0006) and in HE (89.7 [76.8-93.4%], p=0.003, **Figure 2C**, **eFigure 2I**). No differences were found in neutralizing capacity (p=0.74) and maturation of IgG avidity (p=0.36) in pwMS before anti-CD20 therapy and HE.

Cellular immune response to SARS-CoV-2 vaccinations

Cellular immune responses following two SARS-CoV-2 vaccinations were studied by an SARS-CoV-2 spike protein specific IGRA in all pwMS with a lithium heparinized blood sample available and in all HE. Remarkably, SARS-CoV-2 spike protein specific T cell responses were detectable in all anti-CD20 treated pwMS (26/26, 100%, 95%CI: 87.1-100%), similar to pwMS before anti-CD20 therapy (7/7, 100%, 95%CI: 64.6-100%, p=1), and HE (19/19, 100%, 95%CI: 83.2-100%, p=1, **eTable 2**). Consequently, levels of IFN-γ released by SARS-CoV-2 spike protein specific T cells were similar between the three groups (**Figure 2D, eFigure 2J**).

Altogether, following two vaccinations against SARS-CoV-2, across all humoral immune response parameters, lower proportions of positive outcomes were detected in anti-CD20 treated pwMS than in pwMS before anti-CD20 therapy or in HE (**Figure**

2E, **eTable 2**). In contrast, SARS-CoV-2 specific T cells were detected in all twice-vaccinated anti-CD20 treated pwMS, indicating the generation of a robust cellular immune response.

Factors associated with vaccine-induced antibody responses in anti-CD20 treated pwMS

When analysing all 51 twice-vaccinated anti-CD20 treated pwMS, levels of anti-SARS-CoV-2 S1 IgG increased with increasing time between the last anti-CD20 therapy and the second vaccination (r=0.42, p=0.002, **Figure 3A**). Of note, after an interval of >279 days between the last anti-CD20 therapy and the second vaccination, no anti-SARS-CoV-2 S1 IgG negative patients were detected. Furthermore, in the 26 anti-SARS-CoV-2 S1 IgG antibody reactive anti-CD20 treated pwMS vaccinated twice, a strong positive correlation was observed between the relative avidity indices and the interval between the last anti-CD20 therapy and the second vaccination (r=0.70, p<0.001, **Figure 3B**). Likewise, there was a positive correlation between the PRNT50 titer and the interval between the last anti-CD20 therapy and the second vaccination (r=0.44, p=0.03, **Figure 3C)**.

Anti-SARS-CoV-2 S1 IgG levels were not associated with age (r=-0.007, p=0.96, **eFigure 3A**) or time from the second vaccination to blood withdrawal (r=-0.05, p=0.75, **eFigure 3B**). Likewise, there was no association of relative avidity indices (r=0.18, p=0.46) or the PRNT50 titer (r=0.15, p=0.54) with the interval from the second vaccination to blood withdrawal (data not shown). Furthermore, no associations were observed between anti-SARS-CoV-2 S1 IgG antibody levels and

total serum IgG levels (*r*=0.18, *p*=0.25, **eFigure 3C**) or the cumulative lifetime dose of anti-CD20 therapy (*r*=0.04, *p*=0.78, **eFigure 3D**).

Levels of SARS-CoV-2 S1 specific T cell responses did not correlate with the level of anti-SARS-CoV-2 S1 IgG antibodies (*r*=-0.21, *p*=0.31, **eFigure 3E**) or the interval between last anti-CD20 treatment and the second SARS-CoV-2 vaccination (*r*=-0.31, *p*=0.13, **eFigure 3F**)

SARS-CoV-2 infections in pwMS

Infection with SARS-CoV-2 was defined as either a documented positive SARS-CoV-2 RT-PCR, or detection of reactive SARS-CoV-2 antibodies in at least two of four test systems (anti-SARS-CoV-2 S1 IgG/IgA ELISA, IFT, and SeraSpot® anti-SARS-CoV-2 IgG), or a positive IGRA in pwMS not vaccinated against SARS-CoV-2. According to this definition, 9 pwMS were identified as infected with SARS-CoV-2. Of these, 3 had an RT-PCR confirmed infection and 6 were identified by SARS-CoV-2 specific immune responses. In all 3 patients with RT-PCR confirmed SARS-CoV-2 infection anti-SARS-CoV-2 spike IgG antibodies were detectable by ELISA and/or IFT. Antibodies against the SARS-CoV-2 nucleocapsid, indicating past SARS-CoV-2 infection, were detected in only 2/9 SARS-CoV-2 infected pwMS. T cell responses could be determined in 5/9 SARS-CoV-2 infected patients, in all of whom SARS-CoV-2 specific T cells were identified (**eTables 3 and 4**).

Five of 9 patients were infected with SARS-CoV-2 before initiation of anti-CD20 therapy. In these 5 patients, symptoms of SARS-CoV-2 infection were overall mild to moderate and none of the patients needed hospitalization (**eTable 3**). Of note, 3 of

these 5 patients were first diagnosed with MS after SARS-CoV-2 infection. Four of 9 patients were under anti-CD20 therapy at the time they had symptoms compatible with COVID-19. While symptoms were mostly mild to moderate, one of these patients had a more severe course, including worsening of pre-existing MS symptoms requiring hospitalization but no intensive care treatment (**eTable 4**). Altogether, none of the 9 patients died of COVID-19 and all 9 recovered fully.

For each patient, observation time was defined as the interval between March 5, 2020 and the date of the latest sample collection. The total observation time of anti-CD20 treated pwMS was 169.5 patients years. The total observation time for patients before initiation of anti-CD20 therapy, that is, anti-CD20 therapy-naïve patients, was 51.6 patient years. The detection rate of SARS-CoV-2 infections in anti-CD20 treated pwMS was 2.36/100 patient years. In anti-CD20 therapy-naïve pwMS, it was 9.69/100 patient years. The detection rate of RT-PCR confirmed SARS-CoV-2 cases in the total population of Berlin during the study period was 3.75/100 person years.[21]

Discussion

The key findings of this comprehensive analysis of SARS-CoV-2 specific humoral and cellular immune response in a large cohort of pwMS monitored throughout 17 months of the SARS-CoV-2 pandemic are (1) that levels and functionality of antibody responses to SARS-CoV-2 vaccinations were diminished in anti-CD20 treated patients with MS, but this was attenuated with increasing time from the last anti-CD20 infusion to the second vaccination; (2) that pwMS under anti-CD20 therapy developed robust T cell responses following SARS-CoV-2 vaccinations/infections;

and (3) that the detection rate of SARS-CoV-2 infections in anti-CD20-treated pwMS was similar to that of the general population.

Our current findings extend previous work showing diminished humoral immune responses to SARS-CoV-2 vaccinations in anti-CD20 treated pwMS[8,13,14,22] by demonstrating that not only antibody levels, but also the functionality of SARS-CoV-2 antibodies is reduced in anti-CD20 treated pwMS. Of note, the diminished avidity of SARS-CoV-2 antibodies suggests that B cell depletion by anti-CD20 therapies interferes with normal antibody maturation, which appears relevant also for other vaccinations in patients treated with anti-CD20 therapies.[23]

Importantly, SARS-CoV-2 antibody levels, avidity and neutralizing capacity increased with increasing time from the last anti-CD20 therapy to the second SARS-CoV-2 vaccination in anti-CD20 treated pwMS. This is most likely explained by increasing numbers of reappearing B cells with increasing time after anti-CD20 infusion. Indeed the interval from the last anti-CD20 therapy to the second SARS-CoV-2 vaccination of >279 days after which no negative SARS-CoV-2 IgG patients were identified is consistent with slow B cell repopulation starting about 6 months after the last anti-CD20 infusion.[24]

From a clinical perspective, our data suggest that to enhance humoral immune responses, SARS-CoV-2 vaccinations should be applied as late as possible within the 6 monthly infusion cycles of intravenous anti-CD20 therapy. Furthermore, if clinically justified, one may consider prolonging the infusion interval between anti-CD20 infusions to increase chances of successful SARS-CoV-2 vaccinations.[25]

Finally, the reduced SARS-CoV-2 antibody responses in anti-CD20 treated pwMS suggest that an additional booster vaccination should be considered in this patient population.

Remarkably, all anti-CD20 treated pwMS vaccinated twice and all SARS-CoV-2 infected pwMS in whom T cell responses could be tested had SARS-CoV-2 specific T cells. Together with very recent similar results[6,13,14], these data suggest that B cell depletion in anti-CD20 treated pwMS does not impair the generation of SARS-CoV-2 specific cellular immune responses. As an early and robust SARS-CoV-2 specific T cell response is associated with mild or asymptomatic SARS-CoV-2 infections even in the absence of antibodies [26,27], our findings indicate that SARS-CoV-2 vaccination of anti-CD20 treated pwMS may result in some degree of protection from COVID-19. This supports current recommendations to vaccinate anti-CD20 treated pwMS against COVID-19.[2] Furthermore, generation of SARS-CoV-2 specific T cells might be one explanation for the mild to moderate courses of the 4 SARS-CoV-2 infections in anti-CD20 treated pwMS observed in this study.[14] Nevertheless, further studies on the importance of T cells for protection from severe COVID-19 and their role in clearance of SARS-CoV-2 in anti-CD20 treated pwMS are needed. Beyond SARS-CoV-2, preserved T cell response after mRNA and adenovirus-based vaccines suggest an advantage of these vaccine types in patients under B cell depleting therapies and give reason to further investigate these vaccine types for other pathogens in anti-CD20 treated patients.

Protective immunity against SARS-CoV-2 depends on characteristics of circulating virus strains and the build up of antibody levels, specific T cells, and immune

memory.[11,12,28] Easily assessable correlates of protection, such as antibody or T cell cut-off values, have therefore not been and will possibly not be identified. To analyse the clinical significance of reduced antibody levels, but preserved T cell responses against SARS-CoV-2, longitudinal studies of SARS-CoV-2 breakthrough infections in anti-CD20 treated pwMS vaccinated against SARS-CoV-2 will be required.

Whereas the detection rate of SARS-CoV-2 infected anti-CD20 treated pwMS was similar to that of the total population of Berlin, we cannot exclude that the number of SARS-CoV-2 infections in anti-CD20 treated pwMS is an underestimate, as detection of infections was mainly based on detection of SARS-CoV-2 antibodies, which may be undetectable under anti-CD20 therapy.[29] However, all three SARS-CoV-2 RT-PCR positive patients also had detectable anti-SARS-CoV-2 antibodies, indicating that anti-SARS-CoV-2 specific antibodies can be generated in anti-CD20 treated pwMS upon SARS-CoV-2 infection. Interestingly, the detection rate of SARS-CoV-2 infections was lower in anti-CD20 treated pwMS than in pwMS before initiation of anti-CD20 therapy. One explanation for this finding might be a possible change in behaviour of pwMS receiving anti-CD20 therapy, such as stricter mask wearing and avoidance of potentially risky situations.

Limitations

Limitations of this observational study include lack of data on total lymphocyte and B cell counts at the time of SARS-CoV-2 vaccinations/infections precluding evaluations of these parameters as potential risk factors for low vaccine immunogenicity. Furthermore, given the limited follow-up time of the present study and potentially decreasing SARS-CoV-2 immune responses over time, it will be important to analyse

anti-SARS-CoV-2 antibody and T cell responses in anti-CD20 treated patients also in the long term. Finally, the low numbers of pwMS vaccinated with vaccines other than BNT162b2 precluded formal comparisons of immunogenicity of different vaccines.

Conclusions

This study shows that although levels and functionality of anti-SARS-CoV-2 antibodies are diminished, SARS-CoV-2 specific T cell responses are preserved in SARS-CoV-2 vaccinated or infected anti-CD20 treated pwMS. Preserved T cell responses suggest that anti-CD20 treated pwMS develop at least some degree of protection from COVID-19, supporting SARS-CoV-2 vaccinations in anti-CD20 treated pwMS. A longer interval between anti-CD20 infusions and vaccination may enhance the extent and functionality of SARS-CoV-2 antibody responses. Together with the similar detection rate of SARS-CoV2 infections in pwMS under anti-CD20 treatment and in the general population these data are relevant for guiding treatment decisions and management of SARS-CoV-2 vaccinations in pwMS.

Acknowledgements

We thank Betina Jaenicke, Anita Kaiser-Friedrich, Marie Luisa Schmidt, Patricia Tscheak, Julia Tesch, Johanna Riege, Petra Mackeldanz, and Felix Walper for excellent assistance.

Authors Contributions: Victor M. Corman and Klemens Ruprecht had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Corman, Ruprecht

Acquisition, analysis, or interpretation of data: Schwarz, Otto, Pache, Schindler, Niederschweiberer, Schmidt, Corman, Ruprecht

Drafting of the manuscript: Schwarz, Otto, Corman, Ruprecht

Critical revision of the manuscript for important intellectual content: All authors

Statistical analysis: Schwarz, Otto, Corman, Ruprecht

Administrative, technical, or material support: Corman, Jones, Drosten, Ruprecht, Pache, Schindler, Niederschweiberer

Supervision: Corman, Ruprecht

Conflicts of Interest Disclosures:

VMC is named together with Euroimmun GmbH on a patent application filed recently regarding the diagnostic of SARS-CoV-2 by antibody testing. KR received research support from Novartis Pharma, Merck Serono, German Ministry of Education and Research, European Union (821283-2), Stiftung Charité and Arthur Arnstein Foundation, and travel grants from Guthy Jackson Charitable Foundation. No other disclosures were reported.

Funding/Support:

Parts of this work were supported by grants from the Berlin Institute of Health (BIH) and Berlin University Alliance to CD and VMC. This study was further supported by the German Ministry of Education and Research through Forschungsnetzwerk der Universitätsmedizin zu COVID-19, COVIM, FKZ: 01KX2021 to CD and VMC, and projects VARIPath (01KI2021) to VMC. VMC is a participant in the BIH–Charité Clinician Scientist Program funded by Charité - Universitätsmedizin Berlin and the Berlin Institute of Health. KR is a participant in the BIH Clinical Fellow Program funded by Stiftung Charité. FP is a participant in the BIH-Charité Clinician Scientist Program funded by Charité - Universitätsmedizin Berlin and the Berlin Institute of Health.

Role of the Funder/Sponsor: The funders had no role in the design or conduct of the study; collection, management, or analysis of the data, preparation, approval, and review of the manuscript; and decision to submit the manuscript for publication.

References

1. Sormani MP, De Rossi N, Schiavetti I, et al. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. *Ann Neurol*. 2021;89(4):780-789.

2. Wolf A, Alvarez E. COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy. *Neurol Clin Pract*. 2021;11(4):358-361.

3. Nguyen J, Hardigan P, Kesselman MM, Demory Beckler M. Immunogenicity of The Influenza Vaccine in Multiple Sclerosis Patients: A Systematic Review and Meta-Analysis. *Mult Scler Relat Disord*. 2021;48:102698.

4. Luna G, Alping P, Burman J, et al. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. *JAMA Neurol*. 2020;77(2):184-191.

5. Prosperini L, Tortorella C, Haggiag S, Ruggieri S, Galgani S, Gasperini C. Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies. *J Neurol*. Published online September 17, 2021. doi:10.1007/s00415-021-10803-3

6. Meca-Lallana V, Aguirre C, Beatrizdel Río, Cardeñoso L, Alarcon T, Vivancos J. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies. *Mult Scler Relat Disord*. 2020;44:102306.

7. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. *The Lancet Rheumatology*. Published online August 6, 2021. doi:10.1016/S2665-9913(21)00222-8

8. Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. *Ther Adv Neurol Disord*. 2021;14:17562864211012835.

9. van Kempen ZLE, Strijbis EMM, Al MMCT, et al. SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort. *JAMA Neurol*. 2021;78(7):880-882.

10. Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. *Cell*. 2020;183(1):158-168.e14.

11. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell*. 2021;184(4):861-880.

12. Radbruch A, Chang H-D. A long-term perspective on immunity to COVID. *Nature*. 2021;595(7867):359-360.

13. Brill L, Rechtman A, Zveik O, et al. Humoral and T-Cell Response to SARS-

CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab. *JAMA Neurol*. Published online September 23, 2021. doi:10.1001/jamaneurol.2021.3599

14. Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. *Nat Med*. Published online September 14, 2021. doi:10.1038/s41591-021-01507-2

15. Böhmer MM, Buchholz U, Corman VM, et al. Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. *Lancet Infect Dis*. 2020;20(8):920-928.

16. Schwarz T, Tober-Lau P, Hillus D, et al. Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany. *Emerg Infect Dis*. 2021;27(8):2174-2178.

17. Schrezenmeier E, Bergfeld L, Hillus D, et al. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. *Front Immunol*. 2021;12:690698.

18. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature*. 2020;581(7809):465-469.

19. Hillus D, Schwarz T, Tober-Lau P, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. *Lancet Respir Med*. Published online August 12, 2021. doi:10.1016/S2213-2600(21)00357-X

20. Kreye J, Reincke SM, Kornau H-C, et al. A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. *Cell*. 2020;183(4):1058-1069.e19.

21. Experience. Accessed October 4, 2021. https://experience.arcgis.com/experience/478220a4c454480e823b17327b2bf1d4

22. Deepak P, Kim W, Paley MA, et al. Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2. *medRxiv*. Published online April 9, 2021. doi:10.1101/2021.04.05.21254656

23. Maillart E, Papeix C, Lubetzki C, Roux T, Pourcher V, Louapre C. Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies? *Mult Scler Relat Disord*. 2020;46:102482.

24. Baker D, Pryce G, James LK, Marta M, Schmierer K. The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis. *Mult Scler Relat Disord*. 2020;44:102279.

25. Rolfes L, Pawlitzki M, Pfeuffer S, et al. Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19. *Neurol Neuroimmunol Neuroinflamm*. 2021;8(5). doi:10.1212/NXI.0000000000001035

26. Tan AT, Linster M, Tan CW, et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. *Cell Rep*. 2021;34(6):108728.

27. Steiner S, Schwarz T, Corman VM, et al. Reactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology. *Front Immunol*. 2021;12:687449.

28. McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature*. 2021;590(7847):630-634.

29. Lucchini M, Bianco A, Del Giacomo P, De Fino C, Nociti V, Mirabella M. Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report. *Mult Scler Relat Disord*. 2020;44:102323.

Figure 1: Flowchart of patients with multiple sclerosis and controls analyzed in this study



inf.: infected, vac.: vaccinated

Figure 2: Humoral and cellular SARS-CoV-2 immune response in pwMS



(**A**) Sera of anti-CD20 treated pwMS (anti-CD20), pwMS before anti-CD20 therapy (no anti-CD20) and HE were tested for SARS-CoV-2 specific S1 IgG antibodies. SARS-CoV-2 specific S1 IgG OD ratios among pwMS after two vaccinations, pwMS who were not vaccinated/infected, and pwMS after SARS-CoV-2 infections are shown. The dotted horizontal line represents an OD ratio of 1.1, levels above which indicate the presence of anti-SARS-CoV-2 S1 IgG. (**B**) Functionality of SARS-CoV-2 specific antibodies after two vaccinations was analysed in anti-CD20 treated pwMS, pwMS before anti-CD20 therapy, and HE by determination of neutralizing antibodies using a plaque reduction neutralization test (PRNT) and (**C**) IgG avidity maturation. Dotted horizontal lines indicate relative antibody indices >40%, which were considered borderline, and relative antibody indices >60% which were considered high avidity. (**D**) SARS-CoV-2 specific T cell responses were measured in whole blood samples by IGRA in pwMS and HE vaccinated twice and in pwMS who were not vaccinated/infected. SARS-CoV-2 specific T cells were considered to be present if IFN-γ release was higher than the highest value in the not vaccinated/infected control group (111.41 mIU/ml, dotted horizontal line). (**E**) Heatmap summarizing the percentage of positive outcomes per test in pwMS and HE (results for groups with n<3 were not included). Horizontal lines indicate the median. *P* values were calculated by the non-parametric Kruskal-Wallis test with Dunn's multiple comparisons test.

HE: hospital employees, vac: vaccination, S1: SARS-CoV-2 spike protein S1 domain, IgG: immunoglobulin G, IgA: immunoglobulin A, OD: optical density, IFT: immunofluorescence test, PRNT: plaque reduction neutralization test, IGRA: interferon-γ release assay, IFN-γ: interferon γ, IU: international units, ns: not significant

Figure 3: Parameters associated with vaccine-induced humoral immune response in anti-CD20 treated patients with multiple sclerosis



(**A**) Correlation of anti-SARS-CoV-2 S1 IgG OD ratio and interval from the last anti-CD20 therapy to the second SARS-CoV-2 vaccination in anti-CD20 treated pwMS (n=51). (**B**) Correlation of relative avidity index and (**C**) PRNT50 titer with the interval from the last anti-CD20 therapy to the second SARS-CoV-2 vaccination in anti-SARS-CoV-2 S1 IgG reactive anti-CD20 treated pwMS (n=26). Correlations were calculated by Spearman's method.

S1: SARS-CoV-2 spike protein S1 domain, IgG: immunoglobulin G, OD: optical density, PRNT: plaque reduction neutralization test, d: days

Table 1: Demographic, clinical and treatment characteristics of patients with multiple sclerosis and demographic characteristics of healthy controls

	pwMS under anti-CD20 therapy	pwMS before anti-CD20 therapy	Controls (hospital employees)	*p*-value[a]
Number	181	41	19	-
Age, median (range), years	40 (17-81)	37 (18-67)	31 (22-44)	0.003[b]
female/male (% female)	110/71 (61%)	18/23 (44%)	14/5 (74%)	0.06
RRMS/PPMS (% PPMS)	141/40 (22%)	36/5 (12%)	-	0.15
EDSS, median (range)	2 (0-7.5)	2 (0-7)	-	0.08
Any previous immunotherapy[c], n/total n (%)	108/181 (60%)	20/41 (49%)	-	0.2
At least two previous immunotherapies[c], n/total n (%)	62/108 (57%)	12/20 (60%)	-	0.82
Cumulative dose[d] ocrelizumab per patient, median (range), mg	2400 (600-11400)	600 (300-600)	-	-
Treatment with rituximab before ocrelizumab, n/total n (%)	39/181 (22%)	1/41 (2%)	-	-
Cumulative dose[d] rituximab per patient, median (range), mg	4000 (2000-9000)	[e]	-	-
time from MS diagnosis to first sample collection within this study, median (range), months	60 (1-540)	12 (0-288)	-	<0.0001

[a]Statistical significance of differences in the age of the three groups was assessed by Kruskal-Wallis test; statistical significance of differences in gender, MS type, any previous immunotherapy and at least two previous immunotherapies were assessed by Chi-square test; statistical significance of differences in disease duration and EDSS were assessed by Mann-Whitney-U test

[b]In pairwise comparison with Mann-Whitney-U tests, age did not differ between patients with MS (pwMS) under anti-CD20 therapy and pwMS before anti-CD20 therapy (*p*=0.08), as well as between pwMS before anti-CD20 therapy and hospital employees (HE, *p*=0.09), but HE were younger than pwMS under anti-CD20 therapy (*p*=0.0014)

[c]Details of previous treatments are listed in **eTable 1**

[d]Cumulative lifetime dose of anti-CD20 therapy per patient until August 6, 2021

[e]One patient had previously been treated with a cumulative lifetime dose of 8000 mg rituximab followed by an anti-CD20 treatment free interval of >18 months before anti-CD20 therapy was re-initiated with ocrelizumab during the course of this study

EDSS: Expanded Disability Status Scale, MS: multiple sclerosis, n: number, RRMS: relapsing remitting multiple sclerosis, PPMS: primary progressive multiple sclerosis


222 patients with multiple sclerosis, 397 blood samples collected between 5 March 2020 and 6 August 2021
Hospital employees (HE)
last sampling before anti-CD20 therapy (N=41)
last sampling under anti-CD20 therapy (N=175)
inf./vac. before, last sampling under anti-CD20 therapy (N=6)
neither infected nor vaccinated
N=22 (22 samples)
N=113 (186 samples)
infected
N=2 (2 samples)
N=2 (5 samples)
N=2 (3 samples)
infected & vaccinated twice N=1 (3 samples)
infected & vaccinated once N=1 (2 samples)
vaccinated once
N=3 (3 samples)
N=7 (18 samples)
vaccinated once & infected N=1 (3 samples)
vaccinated twice
N=14 (14 samples)
N=51 (131 samples)
N=3 (6 samples)
N=19 (19 samples)


A
<0.0001
<0.0001
ns
anti-SARS-CoV-2 S1 IgG [OD ratio]
12
10
8
6
4
2
0
anti-CD20
no anti-CD20
HE
anti-CD20
no anti-CD20
anti-CD20
no anti-CD20
after 2nd vaccination
not infected/ vaccinated
infected
B
<0.0001
0.0006
ns
PRNT50 titer
≥640
320
160
80
40
20
<20
anti-CD20
no anti-CD20
HE
after 2nd vaccination
C
<0.0001
0.003
ns
relative avidity index [%]
100
80
60
40
20
0
anti-CD20
no anti-CD20
HE
after 2nd vaccination
D
ns
ns
ns
IFN-γ [mIU/ml]
10^5
10^4
10^3
10^2
10^1
10^0
anti-CD20
no anti-CD20
HE
anti-CD20
no anti-CD20
after 2nd vaccination
not infected/ vaccinated
E
S1 IgG 0 51 100 93 100 100
S1 IgA 14 35 100 86 67 95
RBD IgG 0 33 100 93 100 100
full spike IgG 0 37 67 93 67 100
IFT IgG 29 54 100 93 100 100
PRNT 69 100 93 67 100
IgG Avidity 15 0 77 0 90
IGRA 83 100 100 100 100 100
1st vac
2nd vac
1st vac
2nd vac
2nd vac
2nd vac
under anti-CD20 therapy
before anti-CD20 therapy
vaccinated before, sampling under
HE
100
80
60
40
20
0


A
r= 0.42
p= 0.002
anti-SARS-CoV-2 S1 IgG [OD ratio]
0
2
4
6
8
10
0
100
200
300
400
interval last anti-CD20 therapy/2nd vaccination [d]
B
r= 0.70
p<0.001
relative avidity index [%]
0
20
40
60
80
100
0
100
200
300
400
interval last anti-CD20 therapy/2nd vaccination [d]
C
r= 0.44
p= 0.03
PRNT50 titer
ne
g
50
100
150
200
250
300
350
0
100
200
300
400
interval last anti-CD20 therapy/2nd vaccination [d]